Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.109
+0.005 (5.19%)
At close: Mar 5, 2026, 4:00 PM EST
0.110
+0.001 (0.55%)
Pre-market: Mar 6, 2026, 6:55 AM EST
Quince Therapeutics Stock Forecast
QNCX's stock price has decreased by -92.56% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Quince Therapeutics stock has a target of 10, which predicts an increase of 9,040.77% from the current stock price of 0.11.
Analyst Consensus: Hold
* Price targets were last updated on Mar 24, 2025.
Analyst Ratings
The average analyst rating for Quince Therapeutics stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 30, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +4,470.38% | Jan 29, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +4,470.38% | Dec 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +3,556.31% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -1.31
EPS Next Year
-0.93
from -1.15
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.14 | -0.64 | |||
| Avg | -1.15 | -0.93 | |||
| Low | -1.14 | -1.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.